BOSTON, Aug 26- Billionaire investor William Ackman said on Friday that Jordan Rubin, who had worked closely on Pershing Square Capital Management's controversial investment in battered drug maker Valeant Pharmaceuticals, is leaving the hedge fund. News of Rubin's departure comes roughly three months after William Doyle, another key figure in the bet, left...
Aug 26- Carl Icahn said he did not attempt to sell his Herbalife Ltd stake, and had instead bought more shares in the health supplements maker, rejecting hedge fund manager Bill Ackman's claim that he had been offered some of Icahn's shares. "Completely contrary to what Bill Ackman stated on television today, I have never given Jefferies an order to sell any of our...
Things like Mylan's EpiPen price hikes will keep happening unless these changes are made, former Vermont Gov. Howard Dean says.
Brad Arthur, Black Rock Pharmacy co-owner, shares his take on the rising drug prices and the pharma supply chain.
Ross Muken, Evercore ISI managing director, discusses the pharmaceutical supply chain and profits.
Who gets how much of your healthcare dollar? CNBC's Meg Tirrell explains the drug pipeline.
NEW YORK— Activist investor Carl Icahn insists that he's still in Herbalife's camp, saying he bought 2.3 million more Herbalife shares Friday and that he never gave an order to sell his $1 billion stake in the supplements and weight-loss products company. He is Herbalife's biggest shareholder and defender. The U.S. Federal Trade Commission closed its...
CNBC’s Meg Tirrell reports the latest on Mylan prices and the drug price blame game.
*Approached to buy Herbalife shares- Ackman. Aug 26- Herbalife Ltd's biggest critic, hedge fund manager Bill Ackman, said he had been approached to buy shares in the nutritional supplements maker from billionaire investor Carl Icahn. Ackman, who has bet more than $1 billion against Herbalife, said on CNBC that Icahn's planned stake sale would accelerate the...
Mark Merritt, PCMA president & CEO, and CNBC's Meg Tirrell, talk about predatory pricing accusation in the pharmaceutical industry.
Aug 26- Billionaire investor Carl Icahn was lately in talks to sell his stake in nutritional supplement maker Herbalife Ltd to a group that included hedge fund manager Bill Ackman, the Wall Street Journal reported. Jefferies and Herbalife were not immediately available for comment and Carl Icahn could not be immediately reached outside regular U.S. business...
CNBC's Meg Tirrell reports there is lots of finger-pointing in the pharmaceutical space after Mylan's CEO accuses the system of incentivizing higher drug prices.
Chris Kofinis, a Democratic strategist - who worked for Mylan CEO Heather Bresch's father, Sen. Joe Manchin - criticizes her response to the EpiPen "crisis."
Aggressive marketing tactics have led to the overall perception that the EpiPen is essential. NBC News reports.
The list price of the drug will remain the same, but the company said it would increase the maximum copay assistance program to $300 from $100 for patients who pay for the 2- pak in cash or who are covered by a commercial health insurer. The price of EpiPen has skyrocketed to $600 from $100 since it was acquired by Mylan in 2007.. Ronny Gal, an analyst with Bernstein,...
If Mylan's CEO wants to lower the price of the EpiPen today, she could, Express Scripts' Dr. Steve Miller says.
Steve Miller, Express Scripts chief medical officer, responds to Mylan's CEO Heather Bresch blaming the "middle men" for higher drug prices.
To blame the healthcare system is what Mylan CEO Heather Bresch told CNBC today in explaining why the price of her company's EpiPen has seen price hikes of 400%. CNBC's Meg Tirrell breaks down the pharma supply chain system.
There needs to be more transparency in drug pricing, and Mylan still has a lot of questions to answer, Sen. Charles Grassley said Thursday.
CNBC's Meg Tirrell reports on the Pharmaceutical Care Management Association's response to Mylan blaming "the middlemen" for its EpiPen price hike.